• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Addition to inhaled corticosteroids of leukotriene receptor antagonists versus theophylline for symptomatic asthma: a meta-analysis.白三烯受体拮抗剂与茶碱相比联合吸入糖皮质激素治疗症状性哮喘的荟萃分析
J Thorac Dis. 2015 Apr;7(4):644-52. doi: 10.3978/j.issn.2072-1439.2015.04.12.
2
Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma.对于患有持续性哮喘的成人和青少年,在吸入性糖皮质激素中添加抗白三烯药物。
Cochrane Database Syst Rev. 2017 Mar 16;3(3):CD010347. doi: 10.1002/14651858.CD010347.pub2.
3
Addition of antileukotriene agents to inhaled corticosteroids in children with persistent asthma.在持续性哮喘儿童中,吸入性糖皮质激素联用抗白三烯药物。
Paediatr Child Health. 2014 Nov;19(9):473-4. doi: 10.1093/pch/19.9.473.
4
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.长效β2受体激动剂与抗白三烯药物作为吸入性糖皮质激素治疗慢性哮喘的附加疗法比较
Cochrane Database Syst Rev. 2005 Jan 25(1):CD003137. doi: 10.1002/14651858.CD003137.pub2.
5
Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.长效β2受体激动剂与吸入性糖皮质激素联合用于儿童慢性哮喘治疗。
Cochrane Database Syst Rev. 2015 Nov 24;2015(11):CD007949. doi: 10.1002/14651858.CD007949.pub2.
6
Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.长效β2受体激动剂与抗白三烯药物加用吸入性糖皮质激素治疗慢性哮喘的比较
Cochrane Database Syst Rev. 2014 Jan 24;2014(1):CD003137. doi: 10.1002/14651858.CD003137.pub5.
7
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
8
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.长效β2受体激动剂与抗白三烯药物作为吸入性糖皮质激素治疗慢性哮喘的附加疗法比较
Cochrane Database Syst Rev. 2006 Oct 18(4):CD003137. doi: 10.1002/14651858.CD003137.pub3.
9
Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists.持续性哮喘初始维持治疗的选择:吸入性糖皮质激素和白三烯受体拮抗剂综述
Drugs. 2003;63 Suppl 2:1-20. doi: 10.2165/00003495-200363002-00002.
10
Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma.在持续性哮喘儿童中,将抗白三烯药物添加到吸入性糖皮质激素治疗方案中。
Cochrane Database Syst Rev. 2013 Oct 2(10):CD009585. doi: 10.1002/14651858.CD009585.pub2.

引用本文的文献

1
Basis of preventive and non-pharmacological interventions in asthma.哮喘的预防和非药物干预基础。
Front Public Health. 2023 Oct 18;11:1172391. doi: 10.3389/fpubh.2023.1172391. eCollection 2023.
2
The Role of ASIC1a in Inflammatory Immune Diseases: A Potential Therapeutic Target.ASIC1a在炎症性免疫疾病中的作用:一个潜在的治疗靶点。
Front Pharmacol. 2022 Jul 8;13:942209. doi: 10.3389/fphar.2022.942209. eCollection 2022.
3
The role of nutrition in asthma prevention and treatment.营养在哮喘预防和治疗中的作用。
Nutr Rev. 2020 Nov 1;78(11):928-938. doi: 10.1093/nutrit/nuaa005.
4
Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives.噻托溴铵治疗哮喘:患者选择与展望
Can Respir J. 2018 Jan 21;2018:3464960. doi: 10.1155/2018/3464960. eCollection 2018.

本文引用的文献

1
Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events.慢性哮喘患者使用福莫特罗和吸入性类固醇进行常规治疗:严重不良事件
Cochrane Database Syst Rev. 2013 Jun 7(6):CD006924. doi: 10.1002/14651858.CD006924.pub3.
2
Montelukast for the treatment of asthma in the adult population.孟鲁司特治疗成人哮喘。
Expert Opin Pharmacother. 2011 Sep;12(13):2119-28. doi: 10.1517/14656566.2011.600689. Epub 2011 Jul 22.
3
Addition of theophylline or increasing the dose of inhaled corticosteroid in symptomatic asthma: a meta-analysis of randomized controlled trials.在有症状的哮喘中添加茶碱或增加吸入皮质类固醇的剂量:随机对照试验的荟萃分析。
Yonsei Med J. 2011 Mar;52(2):268-75. doi: 10.3349/ymj.2011.52.2.268.
4
A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma.一项随机、开放标签、对照研究,旨在评估作为吸入性糖皮质激素和长效β2受体激动剂附加治疗药物的控制药物在治疗中重度持续性哮喘中的疗效和安全性。
J Postgrad Med. 2010 Oct-Dec;56(4):270-4. doi: 10.4103/0022-3859.70937.
5
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.长效β2受体激动剂与相同剂量吸入性糖皮质激素联合应用于成人及儿童慢性哮喘的疗效比较
Cochrane Database Syst Rev. 2010 May 12(5):CD005535. doi: 10.1002/14651858.CD005535.pub2.
6
Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis.SMART方法在预防哮喘急性发作方面是否比其他治疗方法更有效?一项荟萃分析。
Monaldi Arch Chest Dis. 2009 Dec;71(4):161-9. doi: 10.4081/monaldi.2009.348.
7
Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials.哮喘患者使用福莫特罗的安全性:来自双盲、随机对照临床试验的综合数据分析。
J Allergy Clin Immunol. 2010 Feb;125(2):390-396.e8. doi: 10.1016/j.jaci.2009.11.036.
8
Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy.沙美特罗的死亡率风险与合用吸入皮质激素治疗的效果的荟萃分析。
Thorax. 2010 Jan;65(1):39-43. doi: 10.1136/thx.2009.116608.
9
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.用于报告评估医疗保健干预措施的系统评价和荟萃分析的PRISMA声明:解释与详述
BMJ. 2009 Jul 21;339:b2700. doi: 10.1136/bmj.b2700.
10
Asthma.哮喘
N Engl J Med. 2009 Mar 5;360(10):1002-14. doi: 10.1056/NEJMra0804579.

白三烯受体拮抗剂与茶碱相比联合吸入糖皮质激素治疗症状性哮喘的荟萃分析

Addition to inhaled corticosteroids of leukotriene receptor antagonists versus theophylline for symptomatic asthma: a meta-analysis.

作者信息

Chen Xin, Kang Ying-Bo, Wang Li-Qing, Li Yun, Luo Yu-Wen, Zhu Zhe, Chen Rui

机构信息

1 Department of Respiratory Diseases, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, China ; 2 Department of Pharmacy, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China ; 3 Department of Pharmacy, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, China ; 4 Department of Respiratory Diseases, SUN Yat-sen Memorial Hospital, SUN Yat-sen University, Guangzhou 510120, China.

出版信息

J Thorac Dis. 2015 Apr;7(4):644-52. doi: 10.3978/j.issn.2072-1439.2015.04.12.

DOI:10.3978/j.issn.2072-1439.2015.04.12
PMID:25973230
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4419319/
Abstract

BACKGROUND

Inhaled corticosteroids (ICSs) are widely used in combination with second controller medications in the management of asthma in adults and children. There lacks a systematic comparison between addition of leukotriene receptor antagonists (LTRAs) and theophylline to ICS. The purpose of this meta-analysis was to evaluate the difference of the efficacy and safety profile of adding either LTRAs or theophylline to ICS in adults and children with symptomatic asthma.

METHODS

Randomised controlled trials (RCTs) published prior to November 2014 were acquired through systematically searching and selected based on the established inclusion criteria for publications. The data extracted from the included studies were further analyzed by a meta-analysis.

RESULTS

We included eight RCTs, of which six recruited adults and two recruited children aged 5 to 14 years. The primary outcomes were changes in lung function from baseline, including forced expiratory volume in the first second (FEV1) and peak expiratory flow (PEF). Overall, addition of LTRAs led to significantly better morning PEF {mean difference (MD) 16.94 [95% confidence interval (CI): 11.49-22.39] L/min, P<0.01} and FEV1 [MD 0.09 (95% CI: 0.03-0.15) L, P=0.005] as compared to addition of theophylline. There were no differences between the two treatments in terms of evening PEF, adverse events, rescue medication use and asthma exacerbation.

CONCLUSIONS

The combination of LTRA and ICS leads to modestly greater improvement in lung function than the combination of theophylline and ICS in the treatment of symptomatic asthma. Long-term trials are required to assess the efficacy and safety of these two therapies.

摘要

背景

吸入性糖皮质激素(ICSs)广泛用于联合使用第二种控制药物来治疗成人和儿童哮喘。目前缺乏关于在ICS基础上加用白三烯受体拮抗剂(LTRAs)与加用茶碱之间的系统比较。本荟萃分析的目的是评估在有症状的成人和儿童哮喘患者中,在ICS基础上加用LTRAs或茶碱的疗效和安全性差异。

方法

通过系统检索获取2014年11月之前发表的随机对照试验(RCTs),并根据既定的纳入标准进行筛选。从纳入研究中提取的数据进一步通过荟萃分析进行分析。

结果

我们纳入了8项RCTs,其中6项招募成人,2项招募5至14岁儿童。主要结局指标是肺功能相对于基线的变化,包括第1秒用力呼气量(FEV1)和呼气峰值流速(PEF)。总体而言,与加用茶碱相比,加用LTRAs导致早晨PEF显著更好{平均差值(MD)16.94[95%置信区间(CI):11.49 - 22.39]L/min,P<0.01}以及FEV1[MD 0.09(95%CI:0.03 - 0.15)L,P = 0.005]。两种治疗在夜间PEF、不良事件、急救药物使用和哮喘急性加重方面无差异。

结论

在治疗有症状的哮喘时,LTRA与ICS联合使用比茶碱与ICS联合使用能使肺功能有适度更大的改善。需要进行长期试验来评估这两种治疗方法的疗效和安全性。